Shyndec Pharmaceutical's Unit Gets Nod to Amend Lipoic Acid Injection's Specification

Shanghai Shyndec Pharmaceutical's (SHA:600420) unit, Shanghai Modern Hasen (Shangqiu) Pharmaceutical, received regulatory approval to increase the specification of its lipoic acid injection,

MT Newswires01:20 ET

Shanghai Shyndec Pharmaceutical (600420.SH): Thioctic Acid Injection Approved for Drug Supplementary Application Notification

On July 18th, Gelunhui reported that Shanghai Shyndec Pharmaceutical's subsidiary, Shanghai XianDai Hassan (Shangqiu) Pharmaceutical Co., Ltd, received the "Drug Supplementary Application Approval Notice" issued by the National Medical Products Administration, approving the increase of 24ml:0.6g specification of thioctic acid injection and passing the consistency evaluation of generic drug quality and efficacy. Thioctic acid injection is used to treat the sensory abnormalities caused by diabetic peripheral neuropathy. According to the Minet database, the national sales of thioctic acid injections in public hospitals in 2023 was RMB 0.521 billion.

Gelonghui FinanceJul 18 05:10 ET

Shanghai Shyndec Pharmaceutical (600420.SH): currently has no plan to implement stock-based incentives.

Shanghai Shyndec Pharmaceutical (600420.SH) stated during a recent visit with institutional investors that the company currently has no plans to implement stock-based incentives. If any arrangements are made in the future, the company will fulfill its obligation of disclosing information in a timely manner.

Gelonghui FinanceJul 15 19:56 ET

Shanghai Shyndec Pharmaceutical (600420.SH): the market demand for penicillin and macrolide active pharmaceutical ingredients is still strong.

On July 16th, Glon Hui reported that Shanghai Shyndec Pharmaceutical (600420.SH) said during a recent visit with institutional investors that in the first half of the year, the company's business development basically continued the operating situation of the first quarter. Demand for penicillin and macrolide active pharmaceutical ingredients (APIs) remains strong. The company has fully utilized its advantages in the industry chain, actively seized market opportunities, adjusted its product structure, and increased the production and sales of high-margin products. Secondly, the company continues to strengthen budget management and strictly control expenses, with sales expenses especially showing a significant year-on-year decrease. Thirdly, the company continues to carry out special projects to improve quality and efficiency by improving its technology and processes.

Gelonghui FinanceJul 15 19:55 ET

Shanghai Shyndec Pharmaceutical (600420.SH): The hydrochloride minaprine tablets have obtained the drug supplementary application approval notice.

Shanghai Shyndec Pharmaceutical (600420.SH) announced that it has received the Approval Notice for Drug Supplemental Application issued by the National Medical Products Administration, approving the increase of 50mg specification of Venlafaxine Hydrochloride Tablets based on the original approved 25mg specification. Venlafaxine is a novel selective serotonin (5-HT) and norepinephrine (NE) reuptake inhibitor (SNRI), which can simultaneously inhibit the reuptake of neurons to 5-HT and NE, thereby increasing the concentration of neurotransmitters in the synaptic gap, promoting synaptic transmission function, and playing an antidepressant effect. Venlafaxine hydrochloride tablets are used for the treatment of...

Gelonghui FinanceJul 15 05:00 ET

Shanghai Shyndec Pharmaceutical (600420.SH): Amoxicillin Clavulanic Acid Potassium Tablets pass generic consistency evaluation.

On July 15th, Gelunhui reported that Shanghai Shyndec Pharmaceutical (600420.SH), a wholly-owned subsidiary of China National Pharmaceutical Group, received the "Drug Supplement Application Approval Notice" issued by the National Medical Products Administration, approving Amoxicillin Clavulanate Potassium Tablets to pass the consistency evaluation of generic drug quality and efficacy. The active ingredients of Amoxicillin Clavulanate Potassium Tablets are Amoxicillin and Clavulanate. Amoxicillin is a broad-spectrum penicillin-type antibiotic, while Clavulanate Potassium itself has only weak antibacterial activity, but has a strong broad-spectrum beta-lactamase inhibition. When used together, it can protect Amoxicillin from beta-lactamase.

Gelonghui FinanceJul 15 04:59 ET